| |
Group AS (N = 59)
|
Group PS (N = 21)
|
Group API: (N = 22)
|
|---|
|
Oizumi classification
|
|
Grade O
|
19 (32.2%)
|
6(28.6%)
|
3 (13.6%)
|
|
Grade I
|
30 (50.8%)
|
7 (33.3%)
|
8 (36.4%)
|
|
Grade II
|
8 (13.6%)
|
7 (33.3%)
|
4(18.2%)
|
|
Grade III
|
2 (3.4%)
|
1 (4.8%)
|
5 (22.7%)
|
|
Grade IV
|
0 (0%)
|
0 (0%)
|
2 (9.1%)
|
|
Retraction (mm)
|
29.1 ± 6.2
|
31.2 ± 10.4
|
37.1 ± 8.7
|
|
Width (mm)
|
34.7 ± 6.0
|
37.2 ± 10.4
|
45.0 + 9.8
|
|
Muscle atrophy (%)
|
|
SSC
|
246.5 ± 83.5
|
220.3 ± 67.4
|
252.1 ± 82.4
|
|
SSP
|
76.2 ± 19.8
|
78.9 ± 18.6
|
71.3 ± 16
|
|
ISP/TM
|
220.4 ± 51.9
|
183.4 ± 38.5
|
187.4 ± 54.8
|
|
Fatty degeneration (%)
|
|
SSC
|
5.35 ± 8.25
|
3.5 ± 5 20
|
6.0 ± 7.23
|
|
SSP
|
7.84 ± 10.24
|
11.42 ± 10.15
|
12.2 ± 9.7
|
|
ISP/IM
|
3.35 ± 4.92
|
8.52 ± 9.23
|
6.05 ± 5.2
|
|
Goutallier classification SSC
|
|
Stage 0
|
24 (40.7%)
|
9 (42.9%)
|
6 (27.3%)
|
|
Stage 1
|
26 (44.1%)
|
8 (38.1%)
|
5 (22.7%)
|
|
Stage 2
|
7 (11.9%)
|
4 (19.0%)
|
9 (40.9%)
|
|
Stage 3
|
2 (3.4%)
|
0 (0%)
|
1 (4.5%)
|
|
Stage 4
|
0 (0%)
|
0 (0%)
|
1 (4.5%)
|
|
Goutallier classification SSP
|
|
Stage 0
|
13 (22%)
|
2 (9.5%)
|
2 (9.0%)
|
|
Stage 1
|
16 (27.1%)
|
5 (23.8%)
|
5 (22.7%)
|
|
Stage 2
|
21 (35.6%)
|
11 (52.4%)
|
10 (45.5%)
|
|
Stage 3
|
7 (11.9%)
|
2 (9.5%)
|
1 (4.5%)
|
|
Stage 4
|
2 (3.4%)
|
1 (4.8%)
|
4 (18.2%)
|
|
Goutallier classification ISP/TM
|
|
Stage 0
|
28 (47.5%)
|
5 (22.7%)
|
5 (22.7%)
|
|
Stage 1
|
26 (44.1%)
|
6 (27.3)
|
9 (40.9%)
|
|
Stage 2
|
3 (5.0%)
|
7 (31.8%)
|
5 (22.7%)
|
|
Stage 3
|
2 (3.4%)
|
3 (13.6%)
|
1 (4.5%)
|
|
Stage 4
|
0 (0%)
|
0 (0%)
|
2 (9.0%)
|
|
GFDI
|
1.02 ± 0.62
|
1.36 + 0.5
|
1.29 ± 0.5
|
-
SSC subscapularis, SSP supraspinatus, ISP/TM infraspinatus/teres minor, GFDI global fatty degeneration index
